IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-59929-2.html
   My bibliography  Save this article

PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases

Author

Listed:
  • Koon Hwee Ang

    (Technology and Research (A*STAR))

  • Min Thura

    (Technology and Research (A*STAR))

  • Queenie Shu Woon Tan

    (Technology and Research (A*STAR))

  • Abhishek Gupta

    (Technology and Research (A*STAR))

  • Kam Yew Kuan

    (Technology and Research (A*STAR))

  • Jie Li

    (Technology and Research (A*STAR))

  • Pei Ling Chia

    (Technology and Research (A*STAR))

  • Beiying Qiu

    (8 College Road)

  • Jimmy Ming Hong

    (Level 6 Discovery Tower)

  • Ke Guo

    (Technology and Research (A*STAR))

  • Xiaomeng Wang

    (Technology and Research (A*STAR)
    8 College Road
    Level 6 Discovery Tower)

  • Xinyi Su

    (Technology and Research (A*STAR)
    Level 6 Discovery Tower
    National University of Singapore
    National University Hospital)

  • Qi Zeng

    (Technology and Research (A*STAR)
    National University of Singapore)

Abstract

Neovascular eye diseases represent a major cause of irreversible blindness. Here, we report the specific upregulation of endogenous PRL3 protein in diseased choroid-RPE in choroidal neovascularization (CNV) mouse model (male), and diseased retina in oxygen-induced retinopathy (OIR) mouse model (mixed gender), indicating PRL3’s role in neovascularization. Intravenous (IV) delivery of anti-PRL3 antibody in CNV model demonstrates superior efficacy in reducing vascular leakage compared to intravitreal (IVT) route due to larger dose permitted by IV. VEGF treatment upregulates endogenous PRL3 protein in human retinal microvascular endothelial cells (HRMECs). Retroviral PRL3 overexpression in HRMECs promotes endothelial proliferation, migration and permeability by facilitating the phosphorylation of ERK1/2, AKT, Paxillin and SRC. However, VEGF-induced proliferation is absent in PRL3-knockout HRMECs. PRL3-zumab, an anti-PRL3 humanized monoclonal antibody, has shown a strong safety profile in ongoing multi-national Phase II trials as an intravenous-administered cancer immunotherapeutic. PRL3’s involvement in ocular pathological angiogenesis suggests the potential of repurposing PRL3-zumab to treat neovascular eye diseases.

Suggested Citation

  • Koon Hwee Ang & Min Thura & Queenie Shu Woon Tan & Abhishek Gupta & Kam Yew Kuan & Jie Li & Pei Ling Chia & Beiying Qiu & Jimmy Ming Hong & Ke Guo & Xiaomeng Wang & Xinyi Su & Qi Zeng, 2025. "PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases," Nature Communications, Nature, vol. 16(1), pages 1-15, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59929-2
    DOI: 10.1038/s41467-025-59929-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-59929-2
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-59929-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Min Thura & Abdul Qader Al-Aidaroos & Abhishek Gupta & Cheng Ean Chee & Soo Chin Lee & Kam Man Hui & Jie Li & Yeoh Khay Guan & Wei Peng Yong & Jimmy So & Wee Joo Chng & Chin Hin Ng & Jianbiao Zhou & L, 2019. "PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein," Nature Communications, Nature, vol. 10(1), pages 1-14, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59929-2. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.